330 related articles for article (PubMed ID: 28825717)
1. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
2. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
[No Abstract] [Full Text] [Related]
3. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
4. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
5. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.
Taskinen MR; Björnson E; Matikainen N; Söderlund S; Rämö J; Ainola MM; Hakkarainen A; Sihlbom C; Thorsell A; Andersson L; Bergh PO; Henricsson M; Romeo S; Adiels M; Ripatti S; Laakso M; Packard CJ; Borén J
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040803
[TBL] [Abstract][Full Text] [Related]
6. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.
Jong MC; Rensen PC; Dahlmans VE; van der Boom H; van Berkel TJ; Havekes LM
J Lipid Res; 2001 Oct; 42(10):1578-85. PubMed ID: 11590213
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism.
Ramms B; Gordts PLSM
Curr Opin Lipidol; 2018 Jun; 29(3):171-179. PubMed ID: 29547399
[TBL] [Abstract][Full Text] [Related]
9. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
10. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.
Qu S; Perdomo G; Su D; D'Souza FM; Shachter NS; Dong HH
J Lipid Res; 2007 Jul; 48(7):1476-87. PubMed ID: 17438339
[TBL] [Abstract][Full Text] [Related]
11. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
Zheng C; Khoo C; Ikewaki K; Sacks FM
J Lipid Res; 2007 May; 48(5):1190-203. PubMed ID: 17314277
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Norata GD; Tsimikas S; Pirillo A; Catapano AL
Trends Pharmacol Sci; 2015 Oct; 36(10):675-687. PubMed ID: 26435212
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
[TBL] [Abstract][Full Text] [Related]
15. Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.
Reyes-Soffer G; Sztalryd C; Horenstein RB; Holleran S; Matveyenko A; Thomas T; Nandakumar R; Ngai C; Karmally W; Ginsberg HN; Ramakrishnan R; Pollin TI
Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):63-72. PubMed ID: 30580564
[TBL] [Abstract][Full Text] [Related]
16. Targeting ApoC-III to Reduce Coronary Disease Risk.
Khetarpal SA; Qamar A; Millar JS; Rader DJ
Curr Atheroscler Rep; 2016 Sep; 18(9):54. PubMed ID: 27443326
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
Zheng C; Khoo C; Furtado J; Sacks FM
Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
[TBL] [Abstract][Full Text] [Related]
18. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
Jong MC; Havekes LM
Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
[TBL] [Abstract][Full Text] [Related]
19. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen.
Qin W; Sundaram M; Wang Y; Zhou H; Zhong S; Chang CC; Manhas S; Yao EF; Parks RJ; McFie PJ; Stone SJ; Jiang ZG; Wang C; Figeys D; Jia W; Yao Z
J Biol Chem; 2011 Aug; 286(31):27769-80. PubMed ID: 21676879
[TBL] [Abstract][Full Text] [Related]
20. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
